Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Investigational multicomponent meningococcal group B vaccine in multiple age groups
NCT04825223Phase 1Terminated
- Sponsor
- Sanofi
- Start
- Mar 2021
- Primary completion
- Jul 2022
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
Phase 1, randomised trial of meningococcal group B vaccine in meningococcal disease (8 arms), sponsored by Sanofi. Primary endpoints: Immediate Adverse Events at 30 minutes, Solicited Injection Site Reactions or Systemic Reactions at 7 days and 6 more. Started Mar 2021; status: terminated.
02
Drugs
meningococcal group B vaccine
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on NCT04825223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04825223.